ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Railways
  • World
    • Economy
    • Politics
    • Markets
  • Survey
  • videos
  • photos
  • More ...
    • VIDEOS
    • PHOTOS
BREAKING NEWS
  • RBI extends implementation of card tokenisation norms by 3 months; deadline extended till 30 September
  • EXCLUSIVE: 'Noida International Airport at Jewar to be jewel in crown of Indian aviation sector' - Know what all is coming up at
  • D-Street Corner: Market gains 2.7% in highly volatile week, investors richer by 5.5 lakh cr; what should investors do on Monday?
  • Sebi allows UPI payment option to invest in public issues of REITs, InvITs with effect from 1 August
  • Netflix lays off 450 employees in two months—Here's what's bothering OTT giant
Read in App
Business News » Companies News

Natco Pharma bullish on India, Brazil, Canada biz for FY20

"...The second driver will be Brazil, so Brazil did not do well for many years, so we had some very good launches this year and so that should drive earnings," he said replying to a query during a recently held Earnings Call of the company.

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Natco Pharma bullish on India, Brazil, Canada biz for FY20
Natco Pharma expects India, Brazil and Canada markets to be its revenue drivers during the current financial year, Photo: www.natcopharma.co.in

Natco Pharma expects India, Brazil and Canada markets to be its revenue drivers during the current financial year, recording growth of 30 per cent to 40 per cent, according to a top company executive.

The India business alone was likely to grow by about 15 per cent to 20 per cent, Natco Vice-Chairman and Chief Executive Officer Rajeev Nannapaneni has said.

"...The second driver will be Brazil, so Brazil did not do well for many years, so we had some very good launches this year and so that should drive earnings," he said replying to a query during a recently held Earnings Call of the company.

Talking about Canada, he said Natco was anticipating a couple of launches and a couple of "favourable settlements".

If they all come through, the city-based drug maker expected the three markets to grow at 30 per cent to 40 per cent, he added.

...India is expecting about eight to 10 launches this year. Brazil we are expecting about three to four launches. Canada also we are expecting about three to four launches that is the major one, Nannapaneni said.

The company has recorded consolidated total revenue of Rs 2,225 crore for the year ended on March 31, 2019 as against Rs. 2,242 crore in the previous year, a slight decline of less than 1 per cent year-over-year.

The net profit for the period on a consolidated basis was Rs.642.4 crore as against Rs.695 crore for the last year showing a decline of 7.6 per cent.

The Indian business stood at Rs 735 crore while that of Canada and Brazil at Rs 96 crore and 33 crore respectively.

...Overall what we are projecting is that we will grow by about 7 per cent to 8 per cent and in topline and also we are expecting that our profits also should grow by about 8 per cent to 10 per cent from where we are today, he said.

The growth would primarily better revenues from its drug Copaxone as projected by its marketing partner Mylan and also improved performance the rest of the world based on new product launches.

Copaxone (glatiramer acetate injection) a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis.

Natco Pharma's marketing partner Mylan had already launched generic version of the same drug in the US market in October 2017.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Natco Pharma
Written By: PTI
Updated: Sun, Jun 09, 2019
04:35 pm
Hyderabad, PTI
RELATED NEWS
Q4 Results 2022: Sun Pharma, Natco Pharma, Omaxe declare March quarter results; key highlights here Q4 Results 2022: Sun Pharma, Natco Pharma, Omaxe declare March quarter results; key highlights here
Natco Pharma shares surge 9% as company launches generic version of Revlimid in US; check brokerage view Natco Pharma shares surge 9% as company launches generic version of Revlimid in US; check brokerage view
Natco Pharma Q2FY22 Results: Net profit down 68% at Rs 65 crore Natco Pharma Q2FY22 Results: Net profit down 68% at Rs 65 crore
Mid-cap Picks With Anil Singhvi: Simi Bhaumik recommends 3 stocks for bumper returns Mid-cap Picks With Anil Singhvi: Simi Bhaumik recommends 3 stocks for bumper returns
Natco Pharma shares jump 20% as partner Mylan's injections get USFDA approval Natco Pharma shares jump 20% as partner Mylan's injections get USFDA approval

LATEST NEWS

Indian markets should start its journey upward by October – know why? Analyst lists out 4 reasons

US one step away from historic gun law reforms

RBI exploring options to ensure customer safety dealing with PPIs issued by non-bank entities

Government extends levy of GST compensation cess till March 2026, finance ministry issues notification

BharatNCAP: Government proposes to implement vehicle safety rating, issues draft notification

This Mukul Agrawal textile stock may grow over 52% on strong export outlook and government initiatives

How has technology changed the face of investing and what lies ahead? Analyst decodes

Net profits of manufacturing companies surged by over 50% in FY22, says RBI

iOS users can now securely save their passwords in Chrome

Two-thirds of MSME loan originations concentrated in Maharashtra, Tamil Nadu, and Delhi: Credit information company data

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
© 2022. India Dot Com Private Limited. All Rights Reserved.
LIVE TV